Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2016

View Archived Issues

Lexicon Pharmaceuticals obtains exclusive rights to LX-9211

Eloxx Pharmaceuticals reports orphan drug designations for ELX-02 from both FDA and EMA

Pfizer reviews key milestones of third quarter 2016

CTDP1 as a novel diagnostic biomarker of Behcet disease

FDA puts full clinical hold on phase II study of BI-505

Mylan submits BLA to FDA for proposed trastuzumab biosimilar

Sentinel Oncology patents p70S6K inhibitors

FORMA Therapeutics discloses mutant IDH1 inhibitors

Positive interim data from an ongoing early clinical trial of CC-31244

Araxes Pharma describes mutant K-RAS, H-RAS or N-RAS inhibitors

Takeda Pharmaceutical develops SPT inhibitors

Shionogi presents P2X7 antagonists

DNAtrix in license agreement with University of Florida to develop novel oncolytic virus platform

Sorrento Therapeutics closes Scilex acquisition

BenevolentAI signs exclusive license agreement with Janssen Pharmaceutica

FDA places clinical hold on Heparc-2004 study of ARC-520

Biotest initiates phase III study of IgG Next Generation for primary immunodeficiency disease

CiRA, Takeda and Yokohama City University enter joint research agreement

ProMIS Neurosciences evaluates prevalence of different amyloid beta prion strains in AD

miR-144-3p/survivin may be useful as a target to overcome chemoresistance in NSCLC

Placon Therapeutics initiates phase I trial of BTP-114 for advanced solid tumors with BRCA mutations

PhaseRx reports positive results from animal study of PRX-OTC

MRC Technology, UCB and University of Leicester form research consortium

FKBP5 methylation levels are decreased in patients with schizophrenia

5T4 oncofetal antigen as a promising target for immune intervention in cancer

Phosphatidylinositol shows promise as a biomarker for bipolar disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...